Design and characterizations of pH-responsive drug delivery vehicles using molecular docking

Figures & data

Table 1. Hydrodynamic size and values of zeta potential of loaded and unloaded MSNPs and CSNPs.

Sample	Size (nm)	Zeta potential (mV)
Mesoporous silica NPs	476	−21.2
Ova-loaded MSNP	461	−17.7
5-FU-loaded MSNP	552	−0.6
Chitosan NPs	226	3.2
Ova-loaded CSNP	654	−3.2
5-FU-loaded CSNP	411	−0.4

Figure 1. X-ray diffractogram of a) CS and CSNPs and b) MSNPs.

Figure 2. FESEM images of a) MSNPs, b) CSNPs, c) Ova-alb-loaded MSNPs, d) 5-FU-loaded MSNP, e) Ova-alb-loaded CSNPs and f) 5-FU-loaded CSNPs.

Figure 3. FTIR spectrum of (a) silica NPs with and without template, (b) CSNPs, (c) ova albumin and ova-albumin-loaded MSNPs and (d) 5-FU and 5-FU-loaded MSNPs.

Figure 4. BET adsorption (a) – desorption (d) isotherm of (a) MSNP and (c) CSNP and differential logarithmic distribution of mesopore size of (b) MSNP and (d) CSNP.

Figure 5. a) UV–vis absorption spectra and b) linear fitting of standard solutions of Ova Alb.

Table 2. Drug loading capacities of ova alb/5-FU-loaded MSNPs and CSNPs.

Sr. No.	Nano carrier	Drug	Absorbance of supernatant
			Abs	µg	Total amount of drug taken µg	Encapsulation capacity %	Encapsulation efficiency %
1.	MSNPs	Ova alb	0.344	1.67	5000	49.98	99.96
		5-FU	0.993	22.82	2500	24.77	99.08
2.	CSNPs	Ova alb	0.175	0.894	130	1.76	99.31
		5-FU	1.214	28.18	130	1.39	78.32

Figure 6. a) UV–vis absorption spectra and b) linear fitting of standard solutions of 5-FU.

Figure 7. Cell viability of (a) Normal (RAW 264.7) cells treated with various dose amounts of the MSNP and CSNP and different concentrations of 5-FU-loaded (b) MSNPs and (c) CSNPs treated with RAW 264.7 and lung cancer cell A459.

Figure 8. Binding affinities of a) Ova alb and MSNPs, b) Ova alb and Chitosan, c) 5-FU and MSNPs and d) 5-FU and chitosan.

Figure 9. Drug release studies at pH 4.6 and 7.4 of a) Ova-loaded MSNPs, b) 5-FU-loaded MSNPs, c) Ova-loaded CSNPs and d) 5-FU-loaded CSNPs.